Cargando…

Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature

BACKGROUND: In recent decades, several political, legislative, judicial, consumer, and commercial processes around the world have advanced legalization efforts for the use of medical cannabis (MC). As the use of MC evolves through legislative reform, with an increase in public acceptance and therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruheel, Mohammad Ali, Gomes, Zoya, Usman, Sana, Homayouni, Pargol, Ng, Jeremy Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515704/
https://www.ncbi.nlm.nih.gov/pubmed/34649577
http://dx.doi.org/10.1186/s12954-021-00547-8
_version_ 1784583666097192960
author Ruheel, Mohammad Ali
Gomes, Zoya
Usman, Sana
Homayouni, Pargol
Ng, Jeremy Y.
author_facet Ruheel, Mohammad Ali
Gomes, Zoya
Usman, Sana
Homayouni, Pargol
Ng, Jeremy Y.
author_sort Ruheel, Mohammad Ali
collection PubMed
description BACKGROUND: In recent decades, several political, legislative, judicial, consumer, and commercial processes around the world have advanced legalization efforts for the use of medical cannabis (MC). As the use of MC evolves through legislative reform, with an increase in public acceptance and therapeutic potential, a need exists to further investigate the facilitators and barriers to MC regulation. METHODS: A scoping review was conducted to identify the facilitators and barriers associated with the implementation of MC regulations. MEDLINE, EMBASE, AMED and PsycINFO databases were systematically searched; no restrictions were placed on geographic location/jurisdiction. Eligible articles included those that evaluated the MC regulatory framework of one or more countries. RESULTS: Twenty-two articles were deemed eligible and included in this review. Themes identified include: (1) effects of conflicts, mindset, and ideology of state population, (2) the use of comparisons to analyze MC regulation, and (3) the need for more knowledge, advice, and empirical/clinical evidence to inform future MC policies. CONCLUSION: Policymakers should be aware of facilitators to the MC regulation implementation process, such as the influence of state and federal congruence, increased transparency, and the incorporation of stakeholder concerns, in order to effectively respond to a growing societal acceptance of MC and its use among patients. Given a comprehensive understanding of these influential factors, policymakers may be better equipped to meet the consumer and commercial demands of a rapidly evolving MC regulatory environment.
format Online
Article
Text
id pubmed-8515704
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85157042021-10-20 Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature Ruheel, Mohammad Ali Gomes, Zoya Usman, Sana Homayouni, Pargol Ng, Jeremy Y. Harm Reduct J Review BACKGROUND: In recent decades, several political, legislative, judicial, consumer, and commercial processes around the world have advanced legalization efforts for the use of medical cannabis (MC). As the use of MC evolves through legislative reform, with an increase in public acceptance and therapeutic potential, a need exists to further investigate the facilitators and barriers to MC regulation. METHODS: A scoping review was conducted to identify the facilitators and barriers associated with the implementation of MC regulations. MEDLINE, EMBASE, AMED and PsycINFO databases were systematically searched; no restrictions were placed on geographic location/jurisdiction. Eligible articles included those that evaluated the MC regulatory framework of one or more countries. RESULTS: Twenty-two articles were deemed eligible and included in this review. Themes identified include: (1) effects of conflicts, mindset, and ideology of state population, (2) the use of comparisons to analyze MC regulation, and (3) the need for more knowledge, advice, and empirical/clinical evidence to inform future MC policies. CONCLUSION: Policymakers should be aware of facilitators to the MC regulation implementation process, such as the influence of state and federal congruence, increased transparency, and the incorporation of stakeholder concerns, in order to effectively respond to a growing societal acceptance of MC and its use among patients. Given a comprehensive understanding of these influential factors, policymakers may be better equipped to meet the consumer and commercial demands of a rapidly evolving MC regulatory environment. BioMed Central 2021-10-14 /pmc/articles/PMC8515704/ /pubmed/34649577 http://dx.doi.org/10.1186/s12954-021-00547-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ruheel, Mohammad Ali
Gomes, Zoya
Usman, Sana
Homayouni, Pargol
Ng, Jeremy Y.
Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature
title Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature
title_full Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature
title_fullStr Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature
title_full_unstemmed Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature
title_short Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature
title_sort facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515704/
https://www.ncbi.nlm.nih.gov/pubmed/34649577
http://dx.doi.org/10.1186/s12954-021-00547-8
work_keys_str_mv AT ruheelmohammadali facilitatorsandbarrierstotheregulationofmedicalcannabisascopingreviewofthepeerreviewedliterature
AT gomeszoya facilitatorsandbarrierstotheregulationofmedicalcannabisascopingreviewofthepeerreviewedliterature
AT usmansana facilitatorsandbarrierstotheregulationofmedicalcannabisascopingreviewofthepeerreviewedliterature
AT homayounipargol facilitatorsandbarrierstotheregulationofmedicalcannabisascopingreviewofthepeerreviewedliterature
AT ngjeremyy facilitatorsandbarrierstotheregulationofmedicalcannabisascopingreviewofthepeerreviewedliterature